SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s drug,
Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims
The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and desist from future violations and to pay a monetary penalty, the SEC said.
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback